- Home
- TLSI vs CLLS Comparison
TLSI vs CLLS Comparison
Compare TLSI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- CLLS
- Stock Information
- Founded
- TLSI 2010
- CLLS 1999
- Country
- TLSI United States
- CLLS France
- Employees
- TLSI N/A
- CLLS N/A
- Industry
- TLSI Medical Specialities
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- CLLS Health Care
- Exchange
- TLSI Nasdaq
- CLLS Nasdaq
- Market Cap
- TLSI 150.0M
- CLLS 260.8M
- IPO Year
- TLSI N/A
- CLLS 2007
- Fundamental
- Price
- TLSI $3.94
- CLLS $2.81
- Analyst Decision
- TLSI Strong Buy
- CLLS Buy
- Analyst Count
- TLSI 5
- CLLS 1
- Target Price
- TLSI $10.90
- CLLS $4.00
- AVG Volume (30 Days)
- TLSI 73.5K
- CLLS 281.1K
- Earning Date
- TLSI 08-12-2025
- CLLS 08-04-2025
- Dividend Yield
- TLSI N/A
- CLLS N/A
- EPS Growth
- TLSI N/A
- CLLS N/A
- EPS
- TLSI N/A
- CLLS N/A
- Revenue
- TLSI $35,990,000.00
- CLLS $63,438,000.00
- Revenue This Year
- TLSI $55.39
- CLLS N/A
- Revenue Next Year
- TLSI $54.89
- CLLS $4.90
- P/E Ratio
- TLSI N/A
- CLLS N/A
- Revenue Growth
- TLSI 45.50
- CLLS 223.09
- 52 Week Low
- TLSI $3.42
- CLLS $1.10
- 52 Week High
- TLSI $6.04
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- TLSI 39.84
- CLLS 60.38
- Support Level
- TLSI $3.42
- CLLS $2.48
- Resistance Level
- TLSI $4.00
- CLLS $2.90
- Average True Range (ATR)
- TLSI 0.36
- CLLS 0.28
- MACD
- TLSI -0.01
- CLLS -0.02
- Stochastic Oscillator
- TLSI 34.75
- CLLS 41.98
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.